Poliomyelitis [clinicaltrials_resource:e0b32b524351c3e9f777c722bfdcd879]
Study of "Post-Polio Syndrome" [clinicaltrials:NCT00001185]Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) [clinicaltrials:NCT00092469]Pentavalent DTaP-Hep B-IPV [clinicaltrials:NCT00133445]Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine [clinicaltrials:NCT00137696]Pilot Study Freeze and Transport Immune Cells [clinicaltrials:NCT00138268]Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine [clinicaltrials:NCT00146835]Immune Response & Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccine. [clinicaltrials:NCT00148941]Immunogenicity and Safety of Pentaxim in South African Infants [clinicaltrials:NCT00254969]Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand [clinicaltrials:NCT00255021]Safety of Imovax Polio in Chinese Infants and Children [clinicaltrials:NCT00258843]Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants [clinicaltrials:NCT00287092]clinicaltrials:NCT00303316clinicaltrials:NCT00304265Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV [clinicaltrials:NCT00319852]Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants [clinicaltrials:NCT00320463]clinicaltrials:NCT00337428Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers [clinicaltrials:NCT00343421]Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV [clinicaltrials:NCT00348387]clinicaltrials:NCT00355121Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age [clinicaltrials:NCT00376779]clinicaltrials:NCT00404651Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly [clinicaltrials:NCT00432042]REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-Old Children [clinicaltrials:NCT00447525]Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months [clinicaltrials:NCT00453570]clinicaltrials:NCT00463437Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine [clinicaltrials:NCT00508261]A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children [clinicaltrials:NCT00514033]Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly [clinicaltrials:NCT00604058]clinicaltrials:NCT00611559Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine [clinicaltrials:NCT00635128]clinicaltrials:NCT00654901Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants [clinicaltrials:NCT00753649]clinicaltrials:NCT00797511clinicaltrials:NCT00831311Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. [clinicaltrials:NCT00871000]Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. [clinicaltrials:NCT00871741]Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly [clinicaltrials:NCT00885157]Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers [clinicaltrials:NCT00920439]Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix™) in Infants [clinicaltrials:NCT00937404]Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) [clinicaltrials:NCT00964028]
condition [clinicaltrials_vocabulary:condition]
Study of "Post-Polio Syndrome" [clinicaltrials:NCT00001185]Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) [clinicaltrials:NCT00092469]Pentavalent DTaP-Hep B-IPV [clinicaltrials:NCT00133445]Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine [clinicaltrials:NCT00137696]Pilot Study Freeze and Transport Immune Cells [clinicaltrials:NCT00138268]Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine [clinicaltrials:NCT00146835]Immune Response & Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccine. [clinicaltrials:NCT00148941]Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS) [clinicaltrials:NCT00160082]Immunogenicity and Safety of Pentaxim in South African Infants [clinicaltrials:NCT00254969]Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand [clinicaltrials:NCT00255021]Safety of Imovax Polio in Chinese Infants and Children [clinicaltrials:NCT00258843]Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants [clinicaltrials:NCT00287092]Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants [clinicaltrials:NCT00290342]clinicaltrials:NCT00303316clinicaltrials:NCT00304265Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV [clinicaltrials:NCT00319852]Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants [clinicaltrials:NCT00320463]Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants [clinicaltrials:NCT00325156]clinicaltrials:NCT00337428Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers [clinicaltrials:NCT00343421]Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV [clinicaltrials:NCT00348387]clinicaltrials:NCT00355121Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age [clinicaltrials:NCT00376779]clinicaltrials:NCT00404651Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly [clinicaltrials:NCT00432042]REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-Old Children [clinicaltrials:NCT00447525]Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months [clinicaltrials:NCT00453570]clinicaltrials:NCT00463437Study of Mental Fatigue in Polio Survivors [clinicaltrials:NCT00487487]Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine [clinicaltrials:NCT00508261]A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children [clinicaltrials:NCT00514033]Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine [clinicaltrials:NCT00514059]Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly [clinicaltrials:NCT00604058]clinicaltrials:NCT00611559Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine [clinicaltrials:NCT00635128]clinicaltrials:NCT00654901Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants [clinicaltrials:NCT00753649]clinicaltrials:NCT00797511clinicaltrials:NCT00831311Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. [clinicaltrials:NCT00871000]
condition browse [clinicaltrials_vocabulary:condition-browse]
Study of "Post-Polio Syndrome" [clinicaltrials:NCT00001185]Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) [clinicaltrials:NCT00092469]Pentavalent DTaP-Hep B-IPV [clinicaltrials:NCT00133445]Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine [clinicaltrials:NCT00137696]Pilot Study Freeze and Transport Immune Cells [clinicaltrials:NCT00138268]Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine [clinicaltrials:NCT00146835]Immune Response & Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccine. [clinicaltrials:NCT00148941]Efficacy and Safety of Xepol (Human Immunoglobulin) in Subjects With Post-Polio Syndrome (PPS) [clinicaltrials:NCT00160082]Immunogenicity and Safety of Pentaxim in South African Infants [clinicaltrials:NCT00254969]Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand [clinicaltrials:NCT00255021]Safety of Imovax Polio in Chinese Infants and Children [clinicaltrials:NCT00258843]Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants [clinicaltrials:NCT00287092]Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants [clinicaltrials:NCT00290342]clinicaltrials:NCT00303316clinicaltrials:NCT00304265Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV [clinicaltrials:NCT00319852]Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants [clinicaltrials:NCT00320463]Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants [clinicaltrials:NCT00325156]clinicaltrials:NCT00337428Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlers [clinicaltrials:NCT00343421]Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV [clinicaltrials:NCT00348387]clinicaltrials:NCT00355121Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age [clinicaltrials:NCT00376779]clinicaltrials:NCT00404651Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly [clinicaltrials:NCT00432042]REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-Old Children [clinicaltrials:NCT00447525]Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months [clinicaltrials:NCT00453570]clinicaltrials:NCT00463437Study of Mental Fatigue in Polio Survivors [clinicaltrials:NCT00487487]Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine [clinicaltrials:NCT00508261]A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children [clinicaltrials:NCT00514033]Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine [clinicaltrials:NCT00514059]Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly [clinicaltrials:NCT00604058]clinicaltrials:NCT00611559Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine [clinicaltrials:NCT00635128]clinicaltrials:NCT00654901Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants [clinicaltrials:NCT00753649]clinicaltrials:NCT00797511clinicaltrials:NCT00831311Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. [clinicaltrials:NCT00871000]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Poliomyelitis [clinicaltrials_resource:e0b32b524351c3e9f777c722bfdcd879]
Bio2RDF identifier
e0b32b524351c3e9f777c722bfdcd879
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:e0b32b524351c3e9f777c722bfdcd879
identifier
clinicaltrials_resource:e0b32b524351c3e9f777c722bfdcd879
title
Poliomyelitis
@en
type
label
Poliomyelitis [clinicaltrials_resource:e0b32b524351c3e9f777c722bfdcd879]
@en
Poliomyelitis